Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines

Table 1 Demographic data and treatment of 96 patients

Patient	n
Gender (females/males)	32/64
Median age at presentation	28
Range	10-71
UC; CD	67; 29
Treatment
6-MP (yes/no)	96/0
5-ASA (yes/no)	90/6
Steroid (yes/no)	55/41
Anti-TNF drugs (yes/no)	36/60

CD: Crohn’s disease.

Table 2 Primer sequence for Sanger sequencing analysis of NUDT15 exon 1 and exon 3

Primer	Primer sequence
NUDT15 exon1 forward	5’-CAAAGCACAACTGTAAGCGACT-3’
NUDT15 exon1 reverse	5’-GAAAGACCCAGCTAGCAAAGAC-3’
NUDT15 exon3 forward	5’-TTGTATAGCCAAGCAAATGCAAAGC-3’
NUDT15 exon3 reverse	5’-TCTGTGTCTGGAATACAATTCAATGAC-3’

Table 3 Genotypes of NUDT15 and TPMT

Patients	Exon1	Exon 3	TPMT
Group A (n = 3)
#1-#3	c.52G > A (p.Val18Ile)	Wild	Wild
Group B (n = 3)
#4-#6	c.36_37insGGAGTC (p.Val18 Val19insGlyVal)	c.415C>T (p.Arg139Cys)	Wild
Group C (n = 18)
#7-#24	Wild	c.415C>T (p.Arg139Cys)	Wild
Group D (n = 72)
#25-#96	Wild	Wild	Wild